Blockade of the protein-protein interaction between the transmembrane programmed cell death 1 protein(PD-1)and its ligand PD-L1 emerges as a promising immunotherapy for treating cancers.Using the technology of mirror-image phage display we developed the first hydrolysis-resistant D-peptide inhibitor to target the PD-1/PD-L1 pathway.